

## Supplementary Tables

### Table of Contents

|   | <b>Page Number</b> |
|---|--------------------|
| Table S1. Baseline characteristics of HCHS/SOL participants                             | 2                  |
| Table S2. Baseline and follow-up visit characteristics of individuals who developed CKD | 3                  |
| Table S3. eGFR and albuminuria categories among U.S. Hispanic/Latinos with incident CKD | 4                  |

**Table S1. Baseline characteristics of HCHS/SOL participants\***

|                                     | <b>Original Cohort<br/>n=16415</b> | <b>Eligible participants<br/>with available<br/>outcome measure<br/>n=9384</b> | <b>Final analysis<br/>cohort<br/>n=8774</b> |
|-------------------------------------|------------------------------------|--|---|
| Age, years                          | 41.1 (40.6, 41.6)                  | 40.2 (39.7, 40.8)  | 40.3 (39.7, 40.8)                           |
| Female sex                          | 52.1 (0.6)                         | 51.2 (0.7)   | 51.6 (0.7)                                  |
| Less than high School education     | 32.2 (0.8)                         | 31.3 (0.9)   | 31.2 (0.9)                                  |
| Annual income <\$20,000             | 47.2 (1.1)                         | 46.7 (1.1)   | 46.6 (1.1)                                  |
| Health insurance                    | 51.0 (1.0)                         | 50.2 (1.1)   | 50.0 (1.1)                                  |
| Spanish language                    | 75.5 (0.9)                         | 75.2 (1.0)   | 75.3 (1.0)                                  |
| Acculturation: Language subscale    | 2.1 (0.03)                         | 2.1 (0.03)   | 2.1 (0.03)                                  |
| US born                             | 22.6 (0.9)                         | 23.3 (0.9)   | 23.2 (0.9)                                  |
| ≥10 yrs in the US                   | 71.9 (1.0)                         | 71.8 (1.1)   | 71.3 (1.1)                                  |
| Diabetes                            | 15.8 (0.5)                         | 13.1 (0.5)   | 12.7 (0.5)                                  |
| Hypertension                        | 24.2 (0.7)                         | 21.3 (0.7)   | 21.2 (0.7)                                  |
| Cardiovascular disease              | 5.5 (0.3)                          | 4.9 (0.3)  | 4.6 (0.3)                                   |
| Current smoker                      | 19.8 (0.6)                         | 20.1 (0.7)   | 19.8 (0.7)                                  |
| Physically inactive                 | 20.7 (0.6)                         | 20.1 (0.7)   | 20.2 (0.7)                                  |
| Systolic BP, mm Hg                  | 120 (119, 120)                     | 119 (118, 119)   | 118.5 (118.0, 119.1)                        |
| Diastolic BP, mm Hg                 | 72 (72, 73)                        | 72 (71, 72)  | 71.6 (71.2, 72.0)                           |
| SBP >140 or DBP >90 mmHg            | 12.5 (0.5)                         | 10.7 (0.5)   | 10.7 (0.5)                                  |
| Waist circumference, cm             | 97.5 (97.0, 97.9)                  | 97.0 (96.6, 97.5)  | 97.0 (96.5, 97.5)                           |
| Body mass index, kg/m <sup>2</sup>  | 29.4 (29.2, 29.6)                  | 29.3 (29.1, 29.5)  | 29.3 (29.0, 29.5)                           |
| Obesity (BMI ≥30kg/m <sup>2</sup> ) | 40.0 (0.7)                         | 39.1 (0.8)   | 39.2 (0.8)                                  |
| ACEi/ARB use                        | 11.7 (0.4)                         | 9.9 (0.4)  | 9.8 (0.4)                                   |
| Statin use                          | 8.2 (0.3)                          | 7.0 (0.4)  | 7.1 (0.4)                                   |
| Calcium channel blocker use         | 4.3 (0.3)                          | 3.3 (0.2)  | 3.4 (0.3)                                   |
| Antiplatelet use                    | 1.1 (0.1)                          | 0.9 (0.1)  | 0.9 (0.1)                                   |
| LDL-cholesterol, mg/dL              | 120.2 (119.1, 121.3)               | 120.0 (118.8, 121.2)   | 120.2 (119.0, 121.4)                        |
| HDL-cholesterol, mg/dL              | 48.5 (48.1, 48.9)                  | 48.4 (48.0, 48.8)  | 48.8 (48.3, 49.2)                           |
| HbA1c, %                            | 5.7 (5.7, 5.8)                     | 5.6 (5.6, 5.7)   | 5.6 (5.6, 5.7)                              |
| eGFR, ml/min/1.73m <sup>2</sup>     | 107.0 (0.35)                       | 108.7 (0.35)   | 108.7 (0.35)                                |
| Urine ACR, mg/g, Median (IQR)       | 6.1 (4.3, 10.8)                    | 5.7 (4.1, 8.7)   | 5.7 (4.1, 8.7)                              |
| CRP, mg/L                           | 3.9 (3.7, 4.1)                     | 3.6 (3.4, 3.8)   | 3.6 (3.4, 3.8)                              |

\*Values are presented as mean (95% CI) or % (SE), unless otherwise specified.  
Abbreviations: ACEi, angiotensin converting enzyme inhibitor; ACR albumin to creatinine ratio; ARB, angiotensin receptor blocker; BP, blood pressure; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, high density lipoprotein; LDL, low-density lipoprotein.

**Table S2. Baseline and follow-up visit characteristics of individuals who developed CKD\***

| <b>Variable</b>                                       | <b>Baseline</b>      | <b>Follow-Up</b>     |
|---|----------------------|----------------------|
| eGFR, ml/min/1.73m <sup>2</sup>                       | 97.6 (1.20)          | 89.0 (1.68)          |
| Urine ACR, Median (IQR)                               | 9.5 (6.1, 16.7)      | 40.2 (30.4, 65.7)    |
| Diabetes  | 33.7 (2.8)           | 48.3 (2.9)           |
| Hypertension  | 48.8 (2.9)           | 60.8 (3.0)           |
| Cardiovascular disease                                | 12.1 (1.8)           | 14.8 (1.9)           |
| Current Smoking                                       | 21.9 (2.5)           | 16.4 (2.0)           |
| Systolic BP, mm Hg                                    | 126 (123, 128)       | 131 (129, 134)       |
| Diastolic BP, mm Hg                                   | 74 (73.2, 75.6)      | 75 (73, 77)          |
| SBP >140 or DBP >90 mmHg                              | 24.7 (2.7)           | 35.6 (2.9)           |
| Body mass index kg/m <sup>2</sup> , kg/m <sup>2</sup> | 30.6 (29.9, 31.3)    | 30.6 (29.9, 31.4)    |
| LDL-cholesterol, mg/dL                                | 122.0 (118.3, 125.8) | 115.4 (110.4, 120.3) |
| HbA1c, %  | 6.2 (6.1, 6.4)       | 6.6 (6.4, 6.8)       |

\*Values are presented as mean (95% CI) or % (SE), unless otherwise specified.

Abbreviations: ACR albumin to creatinine ratio; BP, blood pressure; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; LDL, low-density lipoprotein.

**Table S3. eGFR and albuminuria categories among U.S. Hispanic/Latinos with incident CKD**

|   |            |                                  | Albuminuria categories     |                      |                    |     |        |
|---|------------|----------------------------------|----------------------------|----------------------|--------------------|-----|--------|
|   |            |                                  | A1                         | A2                   | A3                 |     |        |
|   |            |                                  | Normal to mildly increased | Moderately increased | Severely increased |     |        |
|   |            |                                  | <30mg/g                    | 30-300mg/g           | >300mg/g           |     |        |
| <b>GFR categories</b><br>(ml/min/1.73m <sup>2</sup> ) | <b>G1</b>  | Normal or high                   | ≥90                        | 0                    | 47.3               | 4.6 | 51.9   |
|   | <b>G2</b>  | Mildly decreased                 | 60-89                      | 0                    | 20.7               | 1.5 | 22.2   |
|   | <b>G3a</b> | Mildly to moderately decreased   | 45-59                      | 17.8                 | 2.8                | 0   | 20.5   |
|   | <b>G3b</b> | Moderately to severely decreased | 30-44                      | 3.4                  | 0.9                | 0.1 | 4.5    |
|   | <b>G4</b>  | Severely decreased               | 15-29                      | 0.5                  | 0.1                | 0.2 | 0.8    |
|   | <b>G5</b>  | Kidney failure                   | <15                        | 0                    | 0                  | 0.1 | 0.1    |
|   |            |                                  |                            | 21.7                 | 71.8               | 6.5 | 100.00 |